> Details

Nientiedt, Cathleen [Author]; Heller, Martina [Author]; Endris, Volker [Author]; Volckmar, Anna-Lena [Author]; Zschäbitz, Stefanie [Author]; Tapia-Laliena, María Angeles [Author]; Jäger, Dirk [Author]; Schirmacher, Peter [Author]; Sültmann, Holger [Author]; Stenzinger, Albrecht [Author]; Hohenfellner, Markus [Author]; Grüllich, Carsten [Author]; Duensing, Stefan [Author]

Mutations in BRCA2 and taxane resistance in prostate cancer

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Mutations in BRCA2 and taxane resistance in prostate cancer
  • Contributor: Nientiedt, Cathleen [Author]; Heller, Martina [Author]; Endris, Volker [Author]; Volckmar, Anna-Lena [Author]; Zschäbitz, Stefanie [Author]; Tapia-Laliena, María Angeles [Author]; Jäger, Dirk [Author]; Schirmacher, Peter [Author]; Sültmann, Holger [Author]; Stenzinger, Albrecht [Author]; Hohenfellner, Markus [Author]; Grüllich, Carsten [Author]; Duensing, Stefan [Author]
  • Published: 4 July 2017
  • Published in: Scientific reports ; 7(2017), Artikel-ID 4574
  • Language: English
  • DOI: 10.1038/s41598-017-04897-x
  • Identifier:
  • Origination:
  • Footnote: Im Titel ist "BRCA2" kursiv geschrieben
  • Description: Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-three men treated with docetaxel for mCRPC were tested for somatic BRCA1/2 mutations of the primary tumor. In a subgroup of patients, BRCA1/2 protein expression was tested as a potential surrogate marker for BRCA1/2 inactivation. Eight of 53 patients (15.1%) harbored a deleterious BRCA2 mutation. No BRCA1 mutation was found. Patients with a BRCA2 mutation showed a response rate of 25% to docetaxel in comparison to 71.1% in men with wildtype BRCA2 (p = 0.019). While the time to develop castration resistance was similar in both subgroups, the overall survival was significantly shorter in patients harboring a BRCA2 mutation. No correlation between the BRCA1/2 protein expression and the response to docetaxel was found. While the presence of a BRCA2 mutation does not preclude a response to docetaxel, there is overall a significant correlation between BRCA2 inactivation and a poor response rate. Our results suggest that a close oncological monitoring of patients with BRCA2 mutations for taxane resistance is warranted.
  • Access State: Open Access